425 related articles for article (PubMed ID: 20182025)
21. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
[TBL] [Abstract][Full Text] [Related]
22. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
23. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
[TBL] [Abstract][Full Text] [Related]
25. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
Villemagne VL; Rowe CC
J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's disease: spect and pet tracers for beta-amyloid imaging.
Valotassiou V; Archimandritis S; Sifakis N; Papatriantafyllou J; Georgoulias P
Curr Alzheimer Res; 2010 Sep; 7(6):477-86. PubMed ID: 20455860
[TBL] [Abstract][Full Text] [Related]
27. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
[TBL] [Abstract][Full Text] [Related]
28. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
29. Protective Factors Modulate the Risk of Beta Amyloid in Alzheimer's Disease.
Zhou B; Tanabe K; Kojima S; Teramukai S; Fukushima M; Neuroimaging Initiative TAD
Behav Neurol; 2020; 2020():7029642. PubMed ID: 33178360
[TBL] [Abstract][Full Text] [Related]
30. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
31. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
[TBL] [Abstract][Full Text] [Related]
32. Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.
Coutinho AM; Busatto GF; de Gobbi Porto FH; de Paula Faria D; Ono CR; Garcez AT; Squarzoni P; de Souza Duran FL; de Oliveira MO; Tres ES; Brucki SMD; Forlenza OV; Nitrini R; Buchpiguel CA
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2666-2680. PubMed ID: 32055966
[TBL] [Abstract][Full Text] [Related]
33. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [
Aghourian M; Legault-Denis C; Soucy JP; Rosa-Neto P; Gauthier S; Kostikov A; Gravel P; Bédard MA
Mol Psychiatry; 2017 Nov; 22(11):1531-1538. PubMed ID: 28894304
[No Abstract] [Full Text] [Related]
34. Early detection of Alzheimer's disease with PET imaging.
Berti V; Osorio RS; Mosconi L; Li Y; De Santi S; de Leon MJ
Neurodegener Dis; 2010; 7(1-3):131-5. PubMed ID: 20197691
[TBL] [Abstract][Full Text] [Related]
35. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
[TBL] [Abstract][Full Text] [Related]
36. Concordance between brain
Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
[TBL] [Abstract][Full Text] [Related]
37. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
38. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
Koychev I; Hofer M; Friedman N
J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
[TBL] [Abstract][Full Text] [Related]
39. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
40. [
Bergeret S; Queneau M; Rodallec M; Curis E; Dumurgier J; Hugon J; Paquet C; Farid K; Baron JC
Eur J Neurol; 2021 May; 28(5):1511-1519. PubMed ID: 33460498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]